Abstract: A forming powder for a forming part with a low tensile anisotropy by additive manufacturing, which can be used for forming the forming part with low tensile anisotropy, a method for forming a forming part with a low tensile anisotropy, and a forming part with a low tensile anisotropy. The forming powder for the forming part with low tensile anisotropy by additive manufacturing includes the following chemical components in terms of mass percentage (wt-%): 0.03%?C?0.09%, 20.50%?Cr?23.00%, 0.50%?Co?2.50%, 8.00%?Mo?10.00%, 0.20%?W?1.00%, 17.00%?Fe?20.00%, 0%<B<0.001%, 0%?Mn?1.00%, 0%?Si?0.15%, 0%?O?0.02%, 0%?N?0.015%, the rest are Ni and inevitable impurities.

Abstract: A non-destructive testing method for lack-of-fusion (LOF) defects, and a testing standard part and a manufacturing method thereof, used for the non-destructive testing of LOF defects of an additive manufacturing workpiece. The manufacturing method of the LOF defect standard part comprises: step A, setting a LOF defect area of the standard part, in the LOF defect area, a proportion of the LOF defects in the LOF defect area is set as a first proportion value; step B, selecting an additive manufacturing forming process for manufacturing the LOF defect area to obtain a first process parameter of the additive manufacturing forming process corresponding to the first proportion value; step C, performing the additive manufacturing forming process based on the first process parameter to form the LOF defect area.

Abstract: A method for prefabricating pore defects by controlling a SLM process, including performing laser scanning on a specified metal melt layer (LY) according to a first scan path (P1) and a second scan path. The first scan path (P1) and the second scan path (P2) have a path overlap zone (A0), the path overlap zone (A0) has a predetermined width, and laser energy input superimposed in the path overlap zone (A0) is controlled to reach a predetermined energy value, whereby keyholes are formed at a plurality of positions in a lengthwise direction of the path overlap zone (A0), the specified metal melt layer (LY) is taken as a defect layer, and the keyholes in the path overlap zone (A0) is taken as pore defects.

Abstract: A preparation method for a metal-modified SAPO molecular sieve is disclosed, characterized in adding a raw powder of the SAPO molecular sieve to a solution containing metal ions for performing ion exchange, and then washing and drying the obtained solid after ion exchange, so as to obtain the metal-modified SAPO molecular sieve. The metal-modified SAPO molecular sieve prepared has a relatively high degree of crystallinity, and the metal elements occupy the ionic positions in the channels and/or cages of the SAPO molecular sieve, and the metal-modified SAPO molecular sieve shows excellent catalytic performance in the catalytic reaction.

Abstract: A preparation method for a metal-modified SAPO molecular sieve is disclosed, characterized in adding a raw powder of the SAPO molecular sieve to a solution containing metal ions for performing ion exchange, and then washing and drying the obtained solid after ion exchange, so as to obtain the metal-modified SAPO molecular sieve. The metal-modified SAPO molecular sieve prepared has a relatively high degree of crystallinity, and the metal elements occupy the ionic positions in the channels and/or cages of the SAPO molecular sieve, and the metal-modified SAPO molecular sieve shows excellent catalytic performance in the catalytic reaction.

Abstract: The present invention relates to a method for preparation of heparin silver, to use of heparin silver in manufacture of medicine for treating burns and/or scalds, to a method of using heparin silver to treat burns and/or scalds, and to a topical preparation containing heparin silver for treating burns and/or scalds. The heparin silver product prepared according to the method of the present invention has a high purity and less impurity. The animal test proved that the medicine made by using heparin silver exhibited effects of accelerating wound healing and reducing scar formation.

Abstract: The present invention discloses a bismuth hyaluronate, characterized in that the bismuth content is from 0.5% to 40%, and the glucuronate content is from 20% to 45%, based on dry weight. Also provided is a method for the preparation of said bismuth hyaluronate comprising reaction of a soluble hyaluronate salt with a bismuth salt in a basic aqueous solution, followed by steps of precipitation, filtration, desalting, dehydrating and drying to obtain the product. Further disclosed is the use of the bismuth hyaluronate in the manufacture of a medicament or health foods for preventing and treating gastrointestinal disorders, in particular ulcerous disorders of the GI tract. It has been proven in animal experiments to show a better therapeutic effect than products of the same type.

Abstract: The present invention discloses a bismuth hyaluronate, characterized in that the bismuth content is from 0.5% to 40%, and the glucuronate content is from 20% to 45%, based on dry weight. Also provided is a method for the preparation of said bismuth hyaluronate comprising reaction of a soluble hyaluronate salt with a bismuth salt in a basic aqueous solution, followed by steps of precipitation, filtration, desalting, dehydrating and drying to obtain the product. Further disclosed is the use of the bismuth hyaluronate in the manufacture of a medicament or health foods for preventing and treating gastrointestinal disorders, in particular ulcerous disorders of the GI tract. It has been proven in animal experiments to show a better therapeutic effect than products of the same type.

Abstract: The present invention relates to a method for preparation of heparin silver, to use of heparin silver in manufacture of medicine for treating burns and/or scalds, to a method of using heparin silver to treat burns and/or scalds, and to a topic topical preparation containing heparin silver for treating burns and/or scalds. The heparin silver product prepared according to the method of the present invention has a high purity and less impurity. The animal test proved that the medicine made by using heparin silver exhibited effects of accelerating wound healing and reducing scar formation.